DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Canada
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
TSND logo

TerrAscend Corp. Stock Price

TSX:TSND Community·CA$327.9m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

TSND Share Price Performance

CA$0.87
-0.20 (-18.69%)
​
CA$1.88
Fair Value
CA$0.87
-0.20 (-18.69%)
53.6% undervalued intrinsic discount
CA$1.88
Fair Value
Price CA$0.87
AnalystConsensusTarget CA$1.88
AnalystHighTarget CA$2.25
AnalystLowTarget CA$1.50
Thu, 4 Sep 25
Fair ValueCA$1.88
Share Pricen/a

TSND Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CA$1.88 53.6% undervalued intrinsic discount

Expanding Adult-Use And Medical Cannabis Markets Will Redefine The Industry

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value CA$2.25 61.3% undervalued intrinsic discount

US Cannabis Legalization And Digital Health Will Unlock Opportunities

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value CA$1.5 42.2% undervalued intrinsic discount

North American Cannabis Will Face Oversupply And Risks Yet Recover

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
TSND logo
TerrAscend
61.3% undervalued intrinsic discount

US Cannabis Legalization And Digital Health Will Unlock Opportunities

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 10 Aug
Read Narrative
TSND logo
TerrAscend
42.2% undervalued intrinsic discount

North American Cannabis Will Face Oversupply And Risks Yet Recover

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 2 Jul
Read Narrative
TSND logo
TerrAscend
53.6% undervalued intrinsic discount

Expanding Adult-Use And Medical Cannabis Markets Will Redefine The Industry

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 1 May 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
TSND logo

TSND: Disciplined M&A And Capital Moves Will Support Future Upside

Fair Value: CA$2.25 61.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
TSND logo

TSND: Uplisting Preparations And New Jersey Dispensary Deal Will Support Upside

Fair Value: CA$1.5 42.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
TSND logo

Expanding Adult-Use And Medical Cannabis Markets Will Redefine The Industry

Fair Value: CA$1.88 53.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with reasonable growth potential.

0 Risks
3 Rewards
View Full Analysis

TerrAscend Corp. Key Details

US$263.9m

Revenue

US$124.6m

Cost of Revenue

US$139.3m

Gross Profit

US$171.0m

Other Expenses

-US$31.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.10
52.77%
-12.04%
254.1%
View Full Analysis

About TSND

Founded
2017
Employees
933
CEO
Ziad Ghanem
WebsiteView website
www.terrascend.com

TerrAscend Corp. cultivates, produces, and sells cannabis products in Canada and the United States. The company manufactures vaporizables, concentrates, topicals, flowers, tinctures, and edibles. It offers its products under the brand name Kind Tree Cannabis, Legend, Valhalla Confections, State Flower Cannabis, Ilera Healthcare, Wana, and Cookies. The company also operates retail dispensaries under the Apothecarium brand name. It serves medical patients and adult-use consumers in North America. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

Recent TSND News & Updates

User avatar
Narrative Update • Aug 10

TSND: Disciplined M&A And Capital Moves Will Support Future Upside

Analysts have adjusted their fair value estimate for TerrAscend to CA$2.25 from CA$2.01 as they revisit assumptions on revenue growth, profit margins and future P/E expectations. What's in the News for TerrAscend TerrAscend executives reiterated on the second quarter 2026 results call that the company is seeking acquisitions that are accretive and focused on markets where it already has scale and infrastructure, with an emphasis on using existing operations to pursue higher vertical revenue and operating leverage.

Recent updates

No updates

TerrAscend Corp. Competitors

GUD logo

Knight Therapeutics

Symbol: TSX:GUD
Market cap: CA$955.8m
DRUG logo

Bright Minds Biosciences

Symbol: CNSX:DRUG
Market cap: CA$875.0m
VREO logo

Vireo Growth

Symbol: CNSX:VREO
Market cap: CA$814.8m
EPRX logo

Eupraxia Pharmaceuticals

Symbol: TSX:EPRX
Market cap: CA$730.2m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide